Oncternal Therapeutics (ONCT) Stock Price, News & Analysis

Company Overview

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.53 to $0.53
• 50-Day Range: $0.53 to $0.53
• 52-Week Range: $0.53 to $7.17
• Volume: N/A
• Average Volume: 99,758 shs
• Market Capitalization: $1.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ONCT Stock Analysis - Frequently Asked Questions

How were Oncternal Therapeutics' earnings last quarter?

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) released its earnings results on Thursday, August, 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.03) by $0.14. The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. Oncternal Therapeutics had a negative trailing twelve-month return on equity of 177.58% and a negative net margin of 1,599.95%.
Read the conference call transcript.

When did Oncternal Therapeutics' stock split?

Oncternal Therapeutics shares reverse split on Monday, January 8th 2024.The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Oncternal Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncternal Therapeutics investors own include NIO (NIO), Walt Disney (DIS), Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONCT
• CIK: 1260990
• Web: www.oncternal.com
• Phone: (858) 434-1113
• Fax: 901-844-8075
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($11.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.48 million
• Net Margins: -1,599.95%
• Pretax Margin: -1,599.95%
• Return on Equity: -177.58%
• Return on Assets: -131.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.39
• Quick Ratio: 2.39

Sales & Book Value

• Annual Sales: $790 thousand
• Price / Sales: 1.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.19 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 2,960,000
• Free Float: 2,628,000
• Market Cap: $1.56 million
• Optionable: No Data
• Beta: 1.18